By Ruqqayah Labidi, Researcher, Global Health Policy Centre Many pharmaceutical companies implement donation schemes to expand access to essential medicines in low- and middle-income countries (LMICs), often as a strategy to mitigate drug market disruptions in high-income countries (HICs). For example, the Gleevec International Patient Assistance Program (GIPAP) provides Imatinib (Gleevec), a targeted cancer therapy, […]
